Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of deadlines, meetings, and online calls has predictably returned. But what can you do? The world, such as it is, keeps spinning. So why not give it a nudge with a delightful cup or three of stimulation? Our choice today is salted caramel mocha, which we likened to a taste of the Jersey Shore. Feel free to join us. Meanwhile, we have assembled the latest list of interesting items for you to peruse. We hope you have a smashing day, and, as always, do keep in touch. We appreciate feedbacks, suggestions, and saucy tips. …

Parents and doctors now have more tools than ever before to help kids manage symptoms of attention deficit hyperactivity disorder. But STAT notes that a looming question is being asked by experts about the next generation of treatments: Are these new drugs and devices any better than what’s come before? At least four new treatments — two drugs, a nerve stimulation device, and a prescription video game — have come to market in recent years to manage or treat symptoms of ADHD. But with new drug formulations and novel approaches, it is difficult to grasp how different options stack up to one another, because there are rarely any studies that compare ADHD treatments head to head.


A handful of European lawmakers are suing the European Commission to fully disclose its Covid-19 vaccine contracts, The EU Observer reports. In response, the European Commission maintained it is bound by confidentiality clauses, but the argument is unlikely to deter the transparency push by the five Green members of the European Parliament, who lodged their lawsuit with the European Union court. They want the commission to reveal the unit price for vaccines, advance payments, donations, liability and indemnification. The European Commission has signed agreements with six vaccine makers, but the published contracts are redacted.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.